Page 321 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

12. COMPLEXES DUPLATINE 277

LEDERER M. et al., Studies of platinum (Il) compounds in aqueous solution. Part 3. The
study of some reactions of K,[PtCI,] and K[PI(NH,)Cl]. Anal. Chim. Acta, 1998, 371,
279-286.
ARIOZ F et al., Determination of cisplatin, transplatin, and amminetrichloroplatinate by
high performance liquid chromatography in one run using 4-methyl-2-thiouracil as
derivatizing agent, Chromatographia, 1999, 49, 562-566.
EL-KHATEEB M. et al., Development of HPLC conditions for valid determination of
hydrolysis products of cisplatin, J. Pharm. Sci., 1999, 88, 319-326.
PHARMACOCINÉTIQUE ET MÉTABOLISME
EGORIN, M.J. et al., Pharmacokinetics and dosage of cis-diammine (1,1-cyclobutane
dicarboxylato) platinum (Il) in patients with impaired renal function, CancerRes., 1984,
44, 5432-5438.
HARLAND S.J. et al., Pharmacokinetics of cis-diammine (1,1-cyclobutane dicarboxylato)
platinum (Il) in patients with normal and impaired renal function, Cancer Res., 1984,
44, 1693-1697.
LABAUNE J.P., Platine total et ultrafiltrable in: Propriétés pharmacocinétiques des médi-
caments, Masson, ed, Paris. 1991, 172-173.
NAGAI N. et al. Decomposition kinetics of cisplatin in human biological fluids, J. Pharm.
Pharmacol., 1996, 48, 918-924.
LUO F.R. et al., Cytotoxicity, cellularuptake, and cellular biotransformations of oxaliplatin
in human colon carcinoma cells, Onco/. Res., 1998, 10, 595-603.
KERN, W et al., Oxaliplatin pharmacokinetics during a four-hour infusion, Clin. Cancer
Res., 1999, 5, 761-765.

MÉCANISME D'ACTION
BARNHAM K.J. et al., lntermolecular Displacement of S-Bound L-Methionine on Plati-
num (Il) by Guanosine 5'-Monophosphate: Implications for the Mechanism of Action
of Anticancer Drugs, J. Chem. Soc., Chem. Commun., 1994, 721-722.
BLOMMAERT F.A. et al., Formation of DNA adducts by the anticancer drug carboplatin :
different nucleotide sequence preferences in vitro and in cells, Biochemistry, 1995, 34,
8474-8480.
ZAMBLE D.B., LIPPARD S.J., Cisplatin and DNA repair in cancer chemotherapy, Trends
Biochem. Sei., 1995, 20, 435-439.
FARID R.S. et al., Differential binding of HMG1, HMG2, and a single HMG box to cispla-
tin-damaged DNA, Toxicol. Appt. Pharmacol., 1996, 141, 532-539.
TAKAHARA P.M. et al., Crystal Structure of the Anticancer Drug Cisplatin Sound to
Duplex DNA, J. Am. Chem. Soc., 1996, 118, 12309-12321.
BERNERS-PRICE S.J. et al., Structural transitions of a GG-platinated DNA duplex indu-
ced by pH, temperature, and box A of high-mobility-group protein 1, Eur. J. Biochem.,
1997, 243, 782-791.
DUNHAM S.U., LIPPARD S.J., DNA Sequence Context and Protein Composition Modu-
late HMG-Domain Protein Recognition of CGisplatin-Modified DNA, Biochemistry,
1997, 36, 11428-11436.